Monique Silva - AnaptysBio Senior Affairs
| ANAB Stock | USD 21.31 0.18 0.84% |
Executive
Monique Silva is Senior Affairs of AnaptysBio
| Address | 10770 Wateridge Circle, San Diego, CA, United States, 92121-5801 |
| Phone | 858 362 6295 |
| Web | https://www.anaptysbio.com |
AnaptysBio Management Efficiency
The company has return on total asset (ROA) of (0.1785) % which means that it has lost $0.1785 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6182) %, meaning that it created substantial loss on money invested by shareholders. AnaptysBio's management efficiency ratios could be used to measure how well AnaptysBio manages its routine affairs as well as how well it operates its assets and liabilities. As of November 11, 2024, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.42. At present, AnaptysBio's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 9.5 M, whereas Total Assets are forecasted to decline to about 354.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chau MBA | CytomX Therapeutics | N/A | |
| Alan MD | Crinetics Pharmaceuticals | 61 | |
| Sarah Ryan | Rhythm Pharmaceuticals | N/A | |
| Yann Mazabraud | Rhythm Pharmaceuticals | 51 | |
| Garlan Adams | Crinetics Pharmaceuticals | N/A | |
| Francis Burrows | Kura Oncology | N/A | |
| Jennifer Lee | Rhythm Pharmaceuticals | 48 | |
| YuWaye MD | CytomX Therapeutics | 56 | |
| Marcia Belvin | CytomX Therapeutics | N/A | |
| JD Esq | Kura Oncology | 53 | |
| Christopher German | Rhythm Pharmaceuticals | 53 | |
| Alastair Garfield | Rhythm Pharmaceuticals | N/A | |
| Kathleen Ford | Kura Oncology | 77 | |
| Dawn Benson | CytomX Therapeutics | N/A | |
| Marc Wilson | Crinetics Pharmaceuticals | 45 | |
| Gayathri Diwakar | Crinetics Pharmaceuticals | N/A | |
| Danielle OlanderMoghadassian | CytomX Therapeutics | N/A | |
| Jim Flaherty | Rhythm Pharmaceuticals | N/A | |
| Dana MD | Crinetics Pharmaceuticals | 68 | |
| MS MBA | Kura Oncology | 50 | |
| Mollie MD | Kura Oncology | N/A | |
Management Performance
| Return On Equity | -1.62 | ||||
| Return On Asset | -0.18 |
AnaptysBio Leadership Team
Elected by the shareholders, the AnaptysBio's board of directors comprises two types of representatives: AnaptysBio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AnaptysBio. The board's role is to monitor AnaptysBio's management team and ensure that shareholders' interests are well served. AnaptysBio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AnaptysBio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Martin Dahl, Senior Research | ||
| Monique Silva, Senior Affairs | ||
| James MD, Advisor | ||
| Beth Mueller, Senior Resources | ||
| Priya Raina, Senior Operations | ||
| Eric Loumeau, General Counsel | ||
| FAAD MBA, Chief Officer | ||
| Benjamin Stone, Chief Officer | ||
| Daniel Faga, Interim Director | ||
| MSc MBA, Advisory | ||
| Dennis Mulroy, Chief Officer | ||
| Douglas MBA, Senior CMC |
AnaptysBio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AnaptysBio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.62 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (2.90) % | ||||
| Operating Margin | (0.76) % | ||||
| Current Valuation | 234.81 M | ||||
| Shares Outstanding | 30.43 M | ||||
| Shares Owned By Insiders | 1.73 % | ||||
| Shares Owned By Institutions | 98.27 % | ||||
| Number Of Shares Shorted | 5.98 M | ||||
| Price To Earning | 81.21 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.05) | Revenue Per Share 2.086 | Quarterly Revenue Growth 8.047 | Return On Assets (0.18) | Return On Equity (1.62) |
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.